Oxaliplatin Kabi (Oxaliplatin)

Oxaliplatin Kabi is used in colorectal cancer treatment pathways and related gastrointestinal malignancies.

• Colorectal cancer: enhances disease control when combined with fluoropyrimidine-based chemotherapy.
• Gastric cancer: contributes to tumor response in combination regimens.
• Pancreatic cancer: used as part of multi‑drug protocols to improve response rates.
• Advanced solid tumours: employed off‑label in clinical trials for various solid tumours.

• Oxaliplatin forms reactive platinum complexes that covalently bind to DNA, creating intra‑ and interstrand cross‑links that inhibit DNA replication and transcription. This DNA damage triggers cellular apoptosis, particularly in rapidly dividing tumor cells, accounting for its antineoplastic activity.

Oxaliplatin Kabi may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Diarrhea: watery stools that may require supportive care.
• Fatigue: generalized tiredness affecting daily activities.
• Myelosuppression: reduced blood cell counts, increasing infection risk.
• Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis or bronchospasm.
• Acute neurotoxicity: sudden onset of muscle cramps or spasms.
• Hemolytic anemia: destruction of red blood cells.
• Thrombotic events: blood clot formation in veins or arteries.
• Cardiotoxicity: arrhythmias or reduced cardiac output.
• Renal impairment: acute kidney injury requiring monitoring.

When handling Oxaliplatin Kabi, clinicians should observe specific safety measures and patient monitoring guidelines.

• Renal function: assess baseline creatinine and monitor during therapy.
• Hepatic function: evaluate liver enzymes before and throughout treatment.
• Neuropathy risk: monitor for sensory changes and adjust dosing if needed.
• Myelosuppression: perform regular complete blood counts.
• Pregnancy and lactation: avoid use unless benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin Kabi can interact with several concomitant medications, influencing efficacy or toxicity.

Major Interactions (Avoid)

• Nephrotoxic agents: concurrent use may exacerbate renal injury.
• Highly protein‑bound drugs: may displace oxalivated   

Moderate   g   t   t  

t  

• Anticoagulants: increased bleeding risk; monitor coagulation parameters.
• Antiemetics with serotonergic activity: potential for serotonin syndrome.
• CYP‑C  

t   t  t   t  

t  

• Drugs  

t   t   t  ":   t  t  t  t  """